Pfizer's abrupt decision left many feeling they had no guidance on what to do next  

September 27, 2024 Check out STAT+

Sponsored By

Courtesy Nana Habib Sickle cell community scrambles to find safe plan after a drug is pulled from the market Doctors were caught between the possibility that prescribing the pills might put patients at risk, but cutting patients off might also put them at risk. By Eric Boodman STAT+ | Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD Market analysts have estimated that the new COPD indication could bring in more than $1 billion in additional annual revenue for Dupixent By Jonathan Wosen Four more health care workers reported illnesses after caring for bird flu case in Missouri It is not clear if any of these people were actually infected with H5N1; they were not tested at the time when they were ill. By Helen Branswell Courtesy Deb Jenssen Dispute over Duchenne gene therapy highlights thorny access issues Elevidys, a gene therapy developed by Sarepta Therapeutics, has received FDA approval. But insurers are not always quick to provide coverage By Andrew Joseph STAT+ | Cassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines Cassava was charged Thursday by the SEC with making misleading claims in 2020 about trials for its Alzheimer's drug, and agreed to pay fines. By Jonathan Wosen Opinion: WHO director general: A breakthrough global agreement on combatting antimicrobial resistance Antimicrobial resistance is associated with more than 1 million deaths a year, with many more projected over the coming decades. By Tedros Adhanom Ghebreyesus Adobe STAT+ | FDA approves schizophrenia drug that could alter how disorder is treated Cobenfy works by stimulating a pair of muscarinic receptors in the brain, that, in turn, control the release of acetylcholine.  By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser